Medical/Pharmaceuticals
Hybribio Calls for Raising International HPV Awareness
GUANGZHOU, China, March 4, 2024 /PRNewswire/ -- March 4th 2024 marks the 7th International HPV Awareness Day, a global campaign proposed by the International Papillomavirus Society (IPVS) since 2018. This year, the theme is One Less Worry. On this special day, Hybribio (300639.SZ) calls for raisi...
2024-03-04 18:47
1864
Results from the Clinical Trial of Qilu Pharmaceutical's Novel Anticancer Agent Iparomlimab and Tuvonralimab (QL1706) Featured in Oral Presentation at the ESGO Annual Meeting
JINAN, China, March 4, 2024 /PRNewswire/ -- The European Society of Gynecological Oncology (ESGO) 2024 Conference has recently made selected abstracts available online. The abstract (abstract # 251) that details results from the Phase II clinical trial (DUBHE-C-206) evaluating the efficacy and s...
2024-03-04 16:53
1814
Caliway Announced Orphan Drug Designation Granted to CBL-514 for the Treatment of Dercum's Disease
* CBL-514 is the first and only drug to receive both Orphan Drug Designation and Fast Track designation for Dercum's disease treatment. NEW TAIPEI CITY, March 4, 2024 /PRNewswire/ -- Caliway Biopharmaceuticals (Caliway) announced that the U.S. Food and Drug Administration (FDA) granted Orphan D...
2024-03-04 16:22
1612
Caliway Announced Orphan Drug Designation Granted to CBL-514 for the Treatment of Dercum's Disease
- CBL-514 is the first and only drug to receive both Orphan Drug Designation and Fast Track designation for Dercum's disease treatment. NEW TAIPEI CITY, March 3, 2024 /PRNewswire/ -- Caliway Biopharmaceuticals (Caliway) announced that the U.S. Food and Drug Administration (FDA) granted Orp...
2024-03-04 07:00
1968
Mezzion Pharmaceuticals Announces Dr. Rahul Rathod of Boston Children's Hospital and Harvard Medical School as the Global Principal Investigator for the Confirmatory Pivotal Phase 3 Trial FUEL-2
FORT LEE, N.J., March 2, 2024 /PRNewswire/ -- Mezzion Pharmaceuticals is a rare disease company conducting the confirmatory pivotal phase 3 clinical trial in Fontan subjects: The Fontan Udenafil Exercise Longitudinal Assessment Trial- 2, or FUEL-2 trial. The company is pleased to announce Dr.Rahu...
2024-03-02 10:26
3235
The 16th Zhang Zhongjing Medicine Culture Festival & Forum on High-quality Development of TCM Takes Place in Nanyang, China
NANYANG, China, March 2, 2024 /PRNewswire/ -- Co-hosted by the Nanyang Chinese Medicine Development Bureau, the China Association of Chinese Medicine (CACM) and the China Association of Traditional Chinese Medicine (CATCM), the Zhang Zhongjing Medicine Culture Festival & Forum on High-quality Dev...
2024-03-02 05:10
3612
NMPA Approves the NDA for CARsgen's BCMA CAR-T Therapy Zevorcabtagene Autoleucel for Relapsed or Refractory Multiple Myeloma
SHANGHAI, March 1, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that today the National Medical Products Administration ("NMPA") ofChi...
2024-03-01 21:50
2095
Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, exarafenib, to Pierre Fabre Laboratories
* Kinnate has entered into an Asset Purchase Agreement (the "APA") with Pierre Fabre Laboratories for global rights to exarafenib and other pan-RAF program assets. * The transaction is in furtherance of Kinnate's previously announced pursuit of strategic alternatives. * This acquisition is ...
2024-03-01 21:35
4071
111 to Announce Fourth Quarter and Fiscal Year 2023 Unaudited Financial Results- Conference Call to Follow
SHANGHAI, March 1, 2024 /PRNewswire/ -- 111, Inc. (NASDAQ: YI) ("111" or the "Company"), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services inChina, today announced that it will report its unaudited financial results...
2024-03-01 17:00
2727
Jacobio Pharma Receives IND Approval for P53 Y220C Activator JAB-30300 in the U.S.
BEIJING, SHANGHAI and BOSTON, March 1, 2024 /PRNewswire/ -- Jacobio Pharma (1167.HK), a clinical-stage oncology company drugging the undruggable targets, today announced it received IND (Investigational New Drug) approval of its self-developed drug JAB-30300 (P53 Y220C activator) from the FDA of ...
2024-03-01 14:55
2395
Innovent Announces First Participant Dosed in a Phase I Study of IBI3002 (an anti-IL-4Rα/TSLP bispecific antibody) in Australia
ROCKVILLE, Md. and SUZHOU, China, March 1, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and ...
2024-03-01 08:00
3245
Metabolon Unveils New Integrated Bioinformatics Platform
Metabolon's cutting-edge bioinformatics platform and unique knowledge base will enable customers to leverage the company's extensive biochemistry experience MORRISVILLE, N.C., Feb. 29, 2024 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide var...
2024-02-29 20:58
1745
SN BioScience received US FDA Orphan Drug Designation for its Nano Anti-Cancer Drug 'SNB-101' on Pancreatic Cancer
SEOUL, South Korea, Feb. 29, 2024 /PRNewswire/ -- SN Bioscience Co. Ltd. (CEO Park Young-hwan) announced onFeb 27 that the US FDA had granted an orphan drug designation for pancreatic cancer for SNB-101 (API: SN-38), a new polymer nanoparticle drug under development, based on the pre-clinical dat...
2024-02-29 18:09
1623
Medidata and Sanofi Vaccines Extend Collaboration to Improve Patient Centricity and Trial Efficiency
Collaboration will harness Medidata Electronic Clinical Outcome Assessment
(eCOA) for remote patient engagement and real-time data capture
SINGAPORE, Feb. 29, 2024 /PRNewswire/ -- Medidata
2024-02-29 17:40
1829
The Adecco Group: Q4 & FULL YEAR 2023 RESULTS
AD HOC ANNOUNCEMENT pursuant to Art. 53 Listing Rules of SIX Swiss Exchange ZURICH, Feb. 29, 2024 /PRNewswire/ -- Q4 & FULL YEAR 2023 RESULTS Continued growth and significant share gains amid tougher markets, strong profitability improvement Q4 HIGHLIGHTS * Revenues +1% yoy, led by Adec...
2024-02-29 13:45
1634
Nin Jiom, Modern Chinese Medicine Pioneer, to Launch NMN Supplement for Healthy Ageing
SINGAPORE, Feb. 29, 2024 /PRNewswire/ -- Nin Jiom
2024-02-29 11:00
1838
MGI Tech & Juntendo University: Changing the Landscape and Unlocking Answers for Patients with Rare Diseases
TOKYO, Feb. 29, 2024 /PRNewswire/ -- Rare diseases have historically been overlooked because they affect relatively few people. While they are identified and addressed differently around the world, there are over known 6,000 rare diseases – characterized by a wide range of disorders and symptoms...
2024-02-29 09:00
2357
Lunit Presents Seven Study Results at ECR 2024: Showcasing AI's Robust Performance in Diverse Clinical Settings
- Lunit to unveil four oral presentations and three poster presentations at ECR 2024, highlighting Lunit INSIGHT's expansive capability, ranging from adaptability in different use cases to the potential to replace a human reader in mammography double-reading settings SEOUL, South Korea, Feb. 28...
2024-02-28 22:03
1390
Skyhawk Therapeutics Has Advanced to the Multiple Ascending Dose Portion of its Phase 1 Study evaluating SKY-0515, a RNA-Targeting Small Molecule for Huntington's Disease
SKY-0515 is a small molecule RNA splicing modifier developed through the company's novel SKYSTAR® platform. Having successfully advanced through single asending dose, SKY-0515 is advancing into the Multiple Ascending Dose portion of its phase 1 study. Huntington's disease is a fatal neurological ...
2024-02-28 21:32
1414
RRD International is now RRD Biopharma Development
RRD Biopharma Development is the dynamic new brand of RRD International. Launched to reflect the company's unique approach to drug development through its successful Product Development Team model. ROCKVILLE, Md., Feb. 28, 2024 /PRNewswire/ -- RRD International has announced today that it launch...
2024-02-28 21:00
1784
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 314 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
8288
Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
2024-11-20 09:00
7685